Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mazouz

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 29, 2001
[In contrast to captopril and enalapril, losartan does not increase mortality of gerbils after carotid ligation]H Mazouz, R Oprisiu, M Monge, et al.
Tissue Antigens|April 30, 2013
Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screeningN Guillaume, H Mazouz, V Piot, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|March 7, 2002
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbilF Dalmay, H Mazouz, J Allard, et al.
Biochemical Pharmacology|July 4, 2001
Protection against ischemia: a physiological function of the renin-angiotensin systemJ Achard, A Fournier, H Mazouz, et al.
Presse Medicale (Paris, France : 1983)|June 9, 1999
[Duality of angiotensin II receptors and risk for stroke and cancer: what is the connection?]A Fournier, A Ghitu, R Darabont, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 16, 1999
[Could angiotensin II type I receptor antagonists have a superior beneficial effect than that of angiotensin II converting enzyme inhibitors with respect to the risk of cerebrovascular accident?]A Fournier, J M Achard, H Mazouz, et al.
Nephrologie|January 1, 1995
[Vitamin D treatment and renal osteodystrophy: indications and modalities]A Fournier, P Morinière, P Yverneau-Hardy, et al.
Nephron|January 1, 1995
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administrationA Fournier, P H Morinière, R Oprisiu, et al.
Clinical Nephrology|July 15, 1999
Risk factors of renal failure progression two years prior to dialysisH Mazouz, I Kacso, A Ghazali, et al.
Presse Medicale (Paris, France : 1983)|October 13, 1998
[Long-term stability of bone mineral density in patients with renal transplant treated with cyclosporine and low doses of corticoids. Protective role of cyclosporine?]F Ezaitouni, P F Westeel, P Fardellone, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 29, 2001
[In contrast to captopril and enalapril, losartan does not increase mortality of gerbils after carotid ligation]H Mazouz, R Oprisiu, M Monge, et al.
Tissue Antigens|April 30, 2013
Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screeningN Guillaume, H Mazouz, V Piot, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|March 7, 2002
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbilF Dalmay, H Mazouz, J Allard, et al.
Biochemical Pharmacology|July 4, 2001
Protection against ischemia: a physiological function of the renin-angiotensin systemJ Achard, A Fournier, H Mazouz, et al.
Presse Medicale (Paris, France : 1983)|June 9, 1999
[Duality of angiotensin II receptors and risk for stroke and cancer: what is the connection?]A Fournier, A Ghitu, R Darabont, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|September 16, 1999
[Could angiotensin II type I receptor antagonists have a superior beneficial effect than that of angiotensin II converting enzyme inhibitors with respect to the risk of cerebrovascular accident?]A Fournier, J M Achard, H Mazouz, et al.
Nephrologie|January 1, 1995
[Vitamin D treatment and renal osteodystrophy: indications and modalities]A Fournier, P Morinière, P Yverneau-Hardy, et al.
Nephron|January 1, 1995
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administrationA Fournier, P H Morinière, R Oprisiu, et al.
Clinical Nephrology|July 15, 1999
Risk factors of renal failure progression two years prior to dialysisH Mazouz, I Kacso, A Ghazali, et al.
Presse Medicale (Paris, France : 1983)|October 13, 1998
[Long-term stability of bone mineral density in patients with renal transplant treated with cyclosporine and low doses of corticoids. Protective role of cyclosporine?]F Ezaitouni, P F Westeel, P Fardellone, et al.
Pageof 2